Literature DB >> 11285548

Imaging of low- and intermediate-grade gliomas.

P E Ricci1, D H Dungan.   

Abstract

Imaging plays a crucial role in the diagnosis and management of low- and intermediate-grade gliomas. In this article, the traditional role of imaging studies in glioma patients and the appearance of some of the more common glial tumors on conventional computed tomography (CT) and magnetic resonance (MR) examinations are reviewed. The impact that MR spectroscopy and MR perfusion imaging have made on the evaluation patients after therapy for glial tumors also is reviewed. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Year:  2001        PMID: 11285548     DOI: 10.1053/srao.2001.21420

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  10 in total

1.  Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy.

Authors:  Casilda Balmaceda; Dana Critchell; Xiangling Mao; Kenneth Cheung; Susan Pannullo; Robert L DeLaPaz; Dikoma C Shungu
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

Review 2.  Gliomas in adults.

Authors:  Thomas Schneider; Christian Mawrin; Cordula Scherlach; Martin Skalej; Raimund Firsching
Journal:  Dtsch Arztebl Int       Date:  2010-11-12       Impact factor: 5.594

Review 3.  Low-grade gliomas.

Authors:  Jimmy Ruiz; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2009-04-19

4.  Diapeutic cancer-targeting alkylphosphocholine analogs may advance management of brain malignancies.

Authors:  Ray R Zhang; Kyle I Swanson; Lance T Hall; Jamey P Weichert; John S Kuo
Journal:  CNS Oncol       Date:  2016-09-12

5.  Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence.

Authors:  Manuel Gómez-Río; Antonio Rodríguez-Fernández; Carlos Ramos-Font; Escarlata López-Ramírez; José Manuel Llamas-Elvira
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-03       Impact factor: 9.236

6.  PTPmu suppresses glioma cell migration and dispersal.

Authors:  Adam M Burgoyne; Juan M Palomo; Polly J Phillips-Mason; Susan M Burden-Gulley; Denice L Major; Anita Zaremba; Shenandoah Robinson; Andrew E Sloan; Michael A Vogelbaum; Robert H Miller; Susann M Brady-Kalnay
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

7.  Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.

Authors:  R Guillevin; C Menuel; S Taillibert; L Capelle; R Costalat; L Abud; C Habas; G De Marco; K Hoang-Xuan; J Chiras; J-N Vallée
Journal:  Br J Cancer       Date:  2011-05-24       Impact factor: 7.640

8.  Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy.

Authors:  P S Murphy; L Viviers; C Abson; I J Rowland; M Brada; M O Leach; A S K Dzik-Jurasz
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

Review 9.  Low-grade gliomas.

Authors:  V W Stieber
Journal:  Curr Treat Options Oncol       Date:  2001-12

Review 10.  Oligodendroglioma.

Authors:  Thomas L Ellis; Volker W Stieber; Rebekah C Austin
Journal:  Curr Treat Options Oncol       Date:  2003-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.